S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:ABUS

Arbutus Biopharma Competitors

$3.24
-0.06 (-1.82 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.20
Now: $3.24
$3.49
50-Day Range
$3.14
MA: $4.01
$4.84
52-Week Range
$0.88
Now: $3.24
$9.02
Volume2.03 million shs
Average Volume3.11 million shs
Market Capitalization$275.11 million
P/E RatioN/A
Dividend YieldN/A
Beta3.15

Competitors

Arbutus Biopharma (NASDAQ:ABUS) Vs. ACRS, ANNX, BTAI, TRIL, ENTA, and ORIC

Should you be buying ABUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Arbutus Biopharma, including Aclaris Therapeutics (ACRS), Annexon (ANNX), BioXcel Therapeutics (BTAI), Trillium Therapeutics (TRIL), Enanta Pharmaceuticals (ENTA), and ORIC Pharmaceuticals (ORIC).

Arbutus Biopharma (NASDAQ:ABUS) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk and Volatility

Arbutus Biopharma has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Arbutus Biopharma and Aclaris Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arbutus Biopharma-1,163.48%N/A-59.66%
Aclaris Therapeutics-941.07%-104.00%-64.47%

Institutional and Insider Ownership

28.4% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 59.1% of Aclaris Therapeutics shares are held by institutional investors. 6.7% of Arbutus Biopharma shares are held by company insiders. Comparatively, 8.2% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Arbutus Biopharma and Aclaris Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arbutus Biopharma02502.71
Aclaris Therapeutics0000N/A

Arbutus Biopharma presently has a consensus price target of $6.2857, suggesting a potential upside of 94.00%. Given Arbutus Biopharma's higher possible upside, equities research analysts clearly believe Arbutus Biopharma is more favorable than Aclaris Therapeutics.

Valuation & Earnings

This table compares Arbutus Biopharma and Aclaris Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$6.01 million45.77$-153,720,000.00($1.62)-2.00
Aclaris Therapeutics$4.23 million260.12$-161,350,000.00($2.25)-9.44

Arbutus Biopharma has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Arbutus Biopharma beats Aclaris Therapeutics on 9 of the 13 factors compared between the two stocks.

Arbutus Biopharma (NASDAQ:ABUS) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Insider and Institutional Ownership

28.4% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 91.2% of Annexon shares are owned by institutional investors. 6.7% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Arbutus Biopharma and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arbutus Biopharma-1,163.48%N/A-59.66%
AnnexonN/A-566.22%-32.99%

Earnings & Valuation

This table compares Arbutus Biopharma and Annexon's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$6.01 million45.77$-153,720,000.00($1.62)-2.00
AnnexonN/AN/A$-37,180,000.00N/AN/A

Annexon has lower revenue, but higher earnings than Arbutus Biopharma.

Analyst Ratings

This is a summary of current ratings and price targets for Arbutus Biopharma and Annexon, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arbutus Biopharma02502.71
Annexon00503.00

Arbutus Biopharma currently has a consensus target price of $6.2857, suggesting a potential upside of 94.00%. Annexon has a consensus target price of $34.3333, suggesting a potential upside of 19.50%. Given Arbutus Biopharma's higher possible upside, equities analysts plainly believe Arbutus Biopharma is more favorable than Annexon.

Summary

Annexon beats Arbutus Biopharma on 5 of the 9 factors compared between the two stocks.

BioXcel Therapeutics (NASDAQ:BTAI) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

48.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 9.4% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 6.7% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for BioXcel Therapeutics and Arbutus Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioXcel Therapeutics00903.00
Arbutus Biopharma02502.71

BioXcel Therapeutics presently has a consensus price target of $102.00, suggesting a potential upside of 130.77%. Arbutus Biopharma has a consensus price target of $6.2857, suggesting a potential upside of 94.00%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Arbutus Biopharma.

Earnings & Valuation

This table compares BioXcel Therapeutics and Arbutus Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-21.88
Arbutus Biopharma$6.01 million45.77$-153,720,000.00($1.62)-2.00

BioXcel Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioXcel Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500.

Profitability

This table compares BioXcel Therapeutics and Arbutus Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioXcel TherapeuticsN/A-74.22%-64.31%
Arbutus Biopharma-1,163.48%N/A-59.66%

Summary

BioXcel Therapeutics beats Arbutus Biopharma on 7 of the 13 factors compared between the two stocks.

Trillium Therapeutics (NASDAQ:TRIL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Valuation & Earnings

This table compares Trillium Therapeutics and Arbutus Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium Therapeutics$120,000.008,566.00$-41,620,000.00($1.38)-7.23
Arbutus Biopharma$6.01 million45.77$-153,720,000.00($1.62)-2.00

Trillium Therapeutics has higher earnings, but lower revenue than Arbutus Biopharma. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trillium Therapeutics and Arbutus Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/A-70.00%-28.84%
Arbutus Biopharma-1,163.48%N/A-59.66%

Insider and Institutional Ownership

67.5% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are held by institutional investors. 6.7% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Trillium Therapeutics and Arbutus Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics01402.80
Arbutus Biopharma02502.71

Trillium Therapeutics currently has a consensus target price of $21.25, indicating a potential upside of 112.93%. Arbutus Biopharma has a consensus target price of $6.2857, indicating a potential upside of 94.00%. Given Trillium Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Arbutus Biopharma.

Risk and Volatility

Trillium Therapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, indicating that its stock price is 215% more volatile than the S&P 500.

Summary

Trillium Therapeutics beats Arbutus Biopharma on 8 of the 14 factors compared between the two stocks.

Arbutus Biopharma (NASDAQ:ABUS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares Arbutus Biopharma and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arbutus Biopharma-1,163.48%N/A-59.66%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Volatility & Risk

Arbutus Biopharma has a beta of 3.15, suggesting that its share price is 215% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Arbutus Biopharma and Enanta Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arbutus Biopharma02502.71
Enanta Pharmaceuticals13402.38

Arbutus Biopharma presently has a consensus price target of $6.2857, indicating a potential upside of 94.00%. Enanta Pharmaceuticals has a consensus price target of $64.6250, indicating a potential upside of 29.53%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Arbutus Biopharma is more favorable than Enanta Pharmaceuticals.

Valuation & Earnings

This table compares Arbutus Biopharma and Enanta Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arbutus Biopharma$6.01 million45.77$-153,720,000.00($1.62)-2.00
Enanta Pharmaceuticals$122.47 million8.22$-36,170,000.00($0.89)-56.06

Enanta Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

28.4% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 6.7% of Arbutus Biopharma shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Arbutus Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Arbutus Biopharma$6.01 million45.77$-153,720,000.00($1.62)-2.00

ORIC Pharmaceuticals has higher earnings, but lower revenue than Arbutus Biopharma.

Profitability

This table compares ORIC Pharmaceuticals and Arbutus Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Arbutus Biopharma-1,163.48%N/A-59.66%

Analyst Ratings

This is a breakdown of recent ratings and target prices for ORIC Pharmaceuticals and Arbutus Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Arbutus Biopharma02502.71

ORIC Pharmaceuticals currently has a consensus target price of $43.4286, indicating a potential upside of 34.66%. Arbutus Biopharma has a consensus target price of $6.2857, indicating a potential upside of 94.00%. Given Arbutus Biopharma's higher possible upside, analysts plainly believe Arbutus Biopharma is more favorable than ORIC Pharmaceuticals.

Insider and Institutional Ownership

73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 6.7% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ORIC Pharmaceuticals beats Arbutus Biopharma on 5 of the 8 factors compared between the two stocks.


Arbutus Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$21.24-0.3%$1.10 billion$4.23 million-15.73Increase in Short Interest
Analyst Revision
Gap Down
Annexon logo
ANNX
Annexon
1.7$28.73-7.9%$1.10 billionN/A0.00
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$44.20-2.3%$1.08 billionN/A-13.12Upcoming Earnings
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-0.5%$1.03 billion$120,000.00-3.70Upcoming Earnings
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.89-3.1%$1.01 billion$122.47 million-27.41
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$32.25-1.0%$994.53 millionN/A0.00Upcoming Earnings
Avid Bioservices logo
CDMO
Avid Bioservices
1.4$17.53-1.3%$994.41 million$59.70 million-175.30News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$17.94-1.7%$984.60 million$227.19 million49.83
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.50-3.3%$962.68 million$35.22 million-6.20
Radius Health logo
RDUS
Radius Health
1.1$20.48-4.8%$960.39 million$173.32 million-8.39Analyst Report
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$23.62-4.2%$955.50 million$800.40 million22.28
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.4$23.30-1.2%$952.25 million$1.52 million-12.39
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$25.89-5.3%$951.85 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$29.14-7.1%$934.35 millionN/A-26.98Increase in Short Interest
Analyst Revision
Epizyme logo
EPZM
Epizyme
1.7$8.97-6.0%$913.01 million$23.80 million-4.02
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$18.11-0.1%$903.27 million$19.89 million-8.54News Coverage
Gap Down
MannKind logo
MNKD
MannKind
1.4$3.63-1.1%$897.18 million$63.04 million-17.28Analyst Report
Analyst Revision
Veru logo
VERU
Veru
1.4$12.43-0.8%$893.87 million$42.59 million-44.39Increase in Short Interest
Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.07-5.4%$873.70 million$150,000.00-5.81Analyst Report
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.96-2.4%$853.17 million$322.36 million128.29Upcoming Earnings
News Coverage
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$20.07-1.8%$842.12 millionN/A-6.92
Humanigen logo
HGEN
Humanigen
1.7$16.10-5.5%$831.03 millionN/A0.00Upcoming Earnings
Unusual Options Activity
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$11.09-4.9%$827.69 million$40.89 million-3.82
Prothena logo
PRTA
Prothena
2.1$20.62-3.6%$824.53 million$810,000.00-8.05Gap Down
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.51-4.3%$817.11 million$296.70 million47.98
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$29.22-0.6%$816.49 million$148.36 million-7.59
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$6.74-0.6%$816.17 million$322.07 million-6.41Upcoming Earnings
Kadmon logo
KDMN
Kadmon
2.0$4.67-1.3%$800.97 million$5.09 million-7.78Earnings Announcement
Analyst Report
Analyst Revision
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.10-0.3%$749.15 million$2.22 million-18.21Earnings Announcement
Analyst Downgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.00-2.5%$727.15 millionN/A0.00Earnings Announcement
Analyst Revision
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$17.10-1.2%$720.90 million$17.26 million-4.75
Merus logo
MRUS
Merus
1.4$22.66-0.4%$716.12 million$31.13 million-7.38Upcoming Earnings
Provention Bio logo
PRVB
Provention Bio
1.4$11.24-1.1%$712.34 millionN/A-7.54Analyst Revision
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.51-4.0%$710.17 million$252 million-2.20Analyst Report
Gap Down
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.79-0.7%$708.66 million$6.83 million-20.40Analyst Report
Analyst Revision
News Coverage
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.31-2.4%$703.17 millionN/A-2.62
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.94-1.6%$697.69 million$19.56 million-20.10Decrease in Short Interest
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$17.62-0.4%$680.20 millionN/A-4.49
OrganiGram logo
OGI
OrganiGram
1.0$2.83-5.3%$657.33 million$64.61 million-4.16Increase in Short Interest
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$33.85-3.0%$647.01 million$9.64 million-5.51Analyst Report
Akouos logo
AKUS
Akouos
1.7$18.17-4.6%$624.74 millionN/A0.00Upcoming Earnings
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.67-4.6%$624.05 million$59.29 million-24.47Earnings Announcement
Analyst Revision
Gap Down
BCEL
Atreca
1.7$16.91-7.3%$622.81 millionN/A-6.00
IDYA
IDEAYA Biosciences
1.1$21.32-7.1%$619.77 millionN/A-11.34
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.04-7.1%$584.61 millionN/A-6.17Earnings Announcement
Analyst Revision
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$43.79-1.2%$570.58 million$195.89 million125.12Earnings Announcement
Analyst Revision
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.42-3.0%$566.55 million$143.01 million-1.03
Ardelyx logo
ARDX
Ardelyx
1.9$6.26-6.5%$564.95 million$5.28 million-6.20Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.99-3.4%$563.08 million$12.52 million-15.77Analyst Upgrade
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.50-0.8%$560.35 millionN/A-15.97
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.